| To: tommysdad who wrote (449) | 7/17/1999 8:22:00 PM | | From: scaram(o)uche | | | |
Weird. Priority date looks like '91, however.
>> BTW, 23 U.S. patents in a year and a half is unbelievable for a company this size --
more than any other biotech I follow. Very productive group (of both scientists
AND attorneys). <<
Finally, a second person has noticed.
- g -
|
| | SIBIA Neurosciences (SIBI) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: scaram(o)uche who wrote (452) | 7/19/1999 8:50:00 PM | | From: John Metcalf | | | |
{Pfizer ethics} Pfizer is becoming its own Viagra joke, having rocketed off for awhile and staying up longer than expected....
www2.nando.net
Pfizer is pleading guilty in a price-fixing scheme. They continued the illegal practice 15 years, and were only fined $20mm, or $1.3mm per year, to view it coldly. Our regulatory apparatus can be quite reasonable to rent!
From curiosity, I read the litigation sections from PFE's 10-Q and 10-K. More good news! Pfizer's attorneys are way too busy to spend much time with Sibia. If they follow a frequent PFE strategy of extending litigation for years, Sibia won't be hurt by it, being able to practice and license their invention in the meantime.
|
| | SIBIA Neurosciences (SIBI) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: scaram(o)uche who wrote (452) | 7/21/1999 9:56:00 AM | | From: scaram(o)uche | | | |
1508Y results negative. Studies insufficiently powered. Lilly gets a year to look at.......... "a trend to significance was noted and significant differences
between doses of altinicline were observed, suggesting a dose-response effect."
biz.yahoo.com |
| | SIBIA Neurosciences (SIBI) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: LLCF who wrote (457) | 7/21/1999 12:39:00 PM | | From: scaram(o)uche | | | |
No, when Lilly took the option, it became their game. Just depends on how strong the trend toward significance was and what the dose response data actually says about the potential.
Program is now well-funded by Lilly, 1553A results coming this quarter. If the 1553 results are negative or "grey", then SIBI turns into a plain old bargain (VGCC/pain, caspase, patents and licenses, BMY/Novartis/Lilly), instead of a potential skyrocket with short fuse.
|
| | SIBIA Neurosciences (SIBI) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
